Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Analgesia-first Strategy Without Hypnotic Sedatives After Neurosurgical Craniotomy
NCT06727435Not yet recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Aug 2026
- Primary completion
- Apr 2028
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Open-label, single-arm trial of remifentanil in agitation and pain, sponsored by Beijing Tiantan Hospital. Primary endpoints: Rate of successful protocol management at 24 hours and Incidence rate of adverse events up to 28 days. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
remifentanil
03
Conditions
agitationpain
Beyond the preview
Go deeper on NCT06727435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06727435.